Paper Information

Journal:   ADVANCED PHARMACEUTICAL BULLETIN   2013 , Volume 3 , Number 2; Page(s) 433 To 437.
 
Paper: 

MESENCHYMAL STEM CELLS: NEW ASPECT IN CELL-BASED REGENERATIVE THERAPY

 
 
Author(s):  MOHAMMADIAN MOZHDEH, SHAMSASENJAN KARIM, LOTFI NEZHAD PARISA, TALEBI MEHDI, JAHEDI MEHDI, NICKHAH HOSSEIN, MINAYI NEDA, MOVASSAGHPOUR ALIAKBAR*
 
* FACULTY OF MEDICINE, TABRIZ UNIVERSITY OF MEDICAL SCIENCES, TABRIZ, IRAN
 
Abstract: 

MSCs are multipotent progenitors which reside in bone marrow. They support hematopoietic stem cells homing, self renewal and differentiation in bone marrow. They can also differentiate into osteoblasts, adipocytes, chondrocytes, myocyates and many other tissues. In vivo, when trauma happens, MSCs operate cell renewal and migrate to the damaged tissues to regenerate that injury. In vitro, MSCs are able to proliferate and differentiate to a variety of cell lineages. This makes them a very hopeful tool for cell-based regenerative therapy for large bone defects, maxillofacial skeletal reconstruction, cardiovascular and spinal cord injury and so many other defects. The most important characteristic that make MSCs an excellent tool for cell replacement is their ability to escape from immune rejection. For therapeutic purposes they usually isolated from human bone marrow or fat and they should proliferate in order to reach an adequate number for implantation. Conventionally DMEM medium supplemented with 10% FBS is used for their expansion, but currently autologous platelet rich products are replaced FBS. Platelet granules contain so many growth factors that can support MSCs proliferation.

 
Keyword(s): MESENCHYMAL STEM CELL, CELL-BASED REGENERATIVE THERAPY, AUTOLOGOUS PLATELET RICH PRODUCT
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 46
 
Latest on Blog
Enter SID Blog